

This is a repository copy of *High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study.*

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/112618/

Version: Accepted Version

Article:

Appelt, AL orcid.org/0000-0003-2792-9218, Pløen, J, Harling, H et al. (6 more authors) (2015) High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. The Lancet Oncology, 16 (8). pp. 919-927. ISSN 1470-2045

https://doi.org/10.1016/S1470-2045(15)00120-5

© 2015. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

Table 1

Patient & treatment characteristics (n=51)

Disease stage	
- T2N0	18 (35%)
- T2N1	9 (18%)
- T3N0	10 (20%)
- T3N1	14 (27%)
Age (median, IQR [years])	67 (58 – 75)
Gender	
- Male	39 (76%)
- Female	12 (24%)
Tumour size (47 pts with data)	
 Diameter (median, IQR [cm]) 	2•8 (2•1-3•5)
 Length (median, IQR [cm]) 	3•4 (2•7 – 4•3)
Distance from sphincter (48 pts with data)	
(median, IQR [cm])	4•8 (4•0 – 5•2)
RT according to protocol	
- Yes	50 (98%)
- No	1 (2%)
Radiotherapy treatment volumes	
(median, IQR [cm ³])	
- CTV-T	45•5 (34•8 – 60•5)
- PTV-T	172•8 (141•0-201•0)
- CTV-N	627•0 (552•8–670•5)
- PTV-N	1363 (1276 – 1462)
Full dose chemotherapy	
- Yes	43 (84%)
	8 (16%)

Table 1: Patient and treatment characteristics.

IQR: Inter-quartile range. RT: Radiotherapy. CTV: Clinical target volume. PTV: Planning target volume. The one patient not receiving RT according to protocol had bilateral hip alloplastics which complicated the planning of concomitant boost IMRT; instead, a single-dose-level plan to 50•4 Gy was delivered and supplemented with 2x5 Gy brachytherapy boosts.